Peter Croucher is a cancer researcher and skeletal biologist. Peter undertook training at the University of Wales College of Medicine and did post-doctoral fellowships in the Department of Medicine in Cambridge and Clinical Biochemistry in Sheffield in the UK.

In 2001 he moved to the Institute of Musculoskeletal Sciences at Oxford University before returning to Sheffield University in 2003 to become Professor of Bone Biology. In 2011 Peter joined the Garvan Institute of Medical Research in Sydney where he is now Director of the Cancer Plasticity and Dormancy Program.

Peter is a leading international authority on cancer cell dormancy and mechanisms of cancer-associated bone disease.

Peter’s has long-standing interests in understanding the cellular and molecular mechanisms that control the skeleton and how cancers develop in bone. He has a particular interest in tumors that metastasize to bone, including breast and prostate cancer, and the blood cancer multiple myeloma.

His research has led to bone-targeted therapies being adopted in clinical practice globally, including zoledronic acid and anti-RANKL therapies. Peter’s current focus is on identifying the seeds of cancer relapse in the skeleton, understanding what controls these rare, disseminated cells, the role they play in disease relapse and developing approaches to stopping relapse before it happens.

Peter also has an interest in developing the next generation of bone-targeted treatments for cancers that grow in the skeleton, bone anabolic therapies.